A COMBINATION THERAPY WITH NIROGACESTAT AND A BCMA-DIRECTED THERAPY AND USES THEREOF

The present disclosure provides methods of treating cancer or light chain amyloidosis in a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the sub...

Full description

Saved in:
Bibliographic Details
Main Authors EDRIS, BADREDDIN, SHEARER, TODD WEBSTER
Format Patent
LanguageEnglish
French
Published 16.09.2021
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides methods of treating cancer or light chain amyloidosis in a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the subject and the uses thereof. La présente invention concerne des procédés de traitement du cancer ou de l'amylose à chaîne légère chez un sujet en ayant besoin, comprenant l'administration d'une polythérapie comprenant une quantité efficace de forme A de dihydrobromure de nirogacestat et d'une thérapie dirigée contre l'antigène de maturation des lymphocytes B (BCMA) au sujet et des utilisations associées.
Bibliography:Application Number: CA20213171267